UCB stock adds patient scholarship to corporate agenda

Published on 11/12/2026 at 17:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB stock gains a new patient-focused initiative as the drugmaker names its first hidradenitis suppurativa scholarship recipients. The move adds a corporate update.

UCB adds new patient initiative

UCB announced 11 inaugural recipients of its hidradenitis suppurativa scholarship.
The program supports education and career-building opportunities for patients and immediate family members.
BIMZELX remains the key commercial focus after fresh psoriatic arthritis data.

UCB, BE0003739530, Illustration mit AI erstellt.

UCB announced on Thursday, November 12, that 11 people had been selected as the first recipients of its annual hidradenitis suppurativa scholarship. The Belgian biopharmaceutical company said each recipient can receive up to 10,000 US dollars to support education and career goals.

The company said the program, launched in June, is open to high school seniors and older people living with hidradenitis suppurativa, as well as immediate family members. Eligible paths include undergraduate and graduate study, certification programs, trade schools and other career-building opportunities.

Patient support broadens corporate focus

According to UCB, the recipients were recognized at a November 5 reception held during the Annual Symposium on Hidradenitis Suppurativa Advances in Tucson, Arizona. Their fields include nursing, teaching, engineering, political science, psychology, environmental design and medicine.

The scholarship is part of UCB's broader patient-support activity, which also includes annual programs for people living with myasthenia gravis or epilepsy. The announcement is a corporate and patient-engagement development rather than a change to the company's product outlook.

BIMZELX remains the investor focus

For investors, the larger current catalyst remains BIMZELX. UCB's BE BOLD study showed numerically higher ACR50 joint-response rates for bimekizumab than for risankizumab through Week 24 in active psoriatic arthritis, while more frequent localized Candida infections remain a safety consideration.

UCB stock traded at 295.10 euros on Lang & Schwarz at 17:16 CET on Thursday, November 12, 2026.